Stifel Nicolaus reaffirmed their buy rating on shares of AnaptysBio, Inc. (NASDAQ:ANAB) in a research note released on Friday. Stifel Nicolaus currently has a $76.00 target price on the biotechnology company’s stock, up from their previous target price of $35.00.

ANAB has been the subject of several other reports. Credit Suisse Group upped their target price on AnaptysBio from $34.00 to $38.00 and gave the company an outperform rating in a report on Friday, August 25th. Royal Bank Of Canada upped their target price on AnaptysBio from $40.00 to $79.00 and gave the company an outperform rating in a report on Tuesday, October 10th. Zacks Investment Research raised AnaptysBio from a hold rating to a buy rating and set a $28.00 target price for the company in a report on Wednesday, August 30th. JMP Securities upped their target price on AnaptysBio from $45.00 to $82.00 and gave the company an outperform rating in a report on Tuesday, October 10th. Finally, Robert W. Baird initiated coverage on AnaptysBio in a report on Monday, July 10th. They set an outperform rating and a $36.00 target price for the company. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The company presently has an average rating of Buy and an average target price of $71.71.

AnaptysBio (ANAB) opened at 66.72 on Friday. The company’s 50-day moving average price is $36.95 and its 200-day moving average price is $27.78. The stock’s market cap is $1.36 billion. AnaptysBio has a 1-year low of $15.17 and a 1-year high of $74.00.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Thursday, August 10th. The biotechnology company reported ($0.13) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.29. The company had revenue of $7.00 million for the quarter, compared to the consensus estimate of $3.45 million. Analysts predict that AnaptysBio will post ($1.99) EPS for the current year.

TRADEMARK VIOLATION WARNING: “AnaptysBio, Inc. (ANAB) Given Buy Rating at Stifel Nicolaus” was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/anaptysbio-inc-anab-given-buy-rating-at-stifel-nicolaus/1635465.html.

In related news, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of the stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $24.35, for a total value of $901,924.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Holdings A/S Novo sold 70,706 shares of the stock in a transaction that occurred on Thursday, August 3rd. The stock was sold at an average price of $23.31, for a total value of $1,648,156.86. Following the completion of the transaction, the insider now directly owns 3,009,949 shares of the company’s stock, valued at $70,161,911.19. The disclosure for this sale can be found here. Insiders sold a total of 1,133,940 shares of company stock valued at $24,223,316 over the last three months.

A number of hedge funds have recently modified their holdings of the stock. Artal Group S.A. lifted its position in AnaptysBio by 459.4% in the second quarter. Artal Group S.A. now owns 250,000 shares of the biotechnology company’s stock worth $5,983,000 after purchasing an additional 205,310 shares during the period. JPMorgan Chase & Co. acquired a new stake in AnaptysBio in the first quarter worth approximately $3,851,000. Geode Capital Management LLC acquired a new stake in AnaptysBio in the first quarter worth approximately $1,522,000. Iguana Healthcare Management LLC acquired a new stake in AnaptysBio in the first quarter worth approximately $1,388,000. Finally, Boxer Capital LLC acquired a new stake in AnaptysBio in the first quarter worth approximately $1,388,000. 71.35% of the stock is owned by institutional investors and hedge funds.

AnaptysBio Company Profile

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.